08:48 AM EDT, 04/01/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its drug Voydeya has been approved by the US Food and Drug Administration as add-on therapy to ravulizumab or eculizumab to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria.

The FDA approval of the drug followed results from a 12-week study that met its primary endpoint of change in hemoglobin from baseline to week 12, and key secondary endpoints, including transfusion avoidance.

Voydeya was granted Breakthrough Therapy designation by the FDA and Priority Medicines status by the European Medicines Agency.

Separately, two advisory groups assessed AstraZeneca ( AZN ) Chief Executive Pascal Soriot's proposed salary of 18.7 million British pounds ($23.6 million) as excessive, and urged shareholders to vote against it at an April 11 general annual meeting, The Financial Times reported. Soriot earned 16.9 million British pounds last year, according to the report.

Price: 67.99, Change: +0.24, Percent Change: +0.35